Tag Archives: Cas9

November, 2018

9 November
CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies

ZUG, Switzerland and CAMBRIDGE, Mass. and GAITHERSBURG, Md., Nov. 09, 2018 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP) and MaxCyte today announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation®Technology to develop CRISPR/Cas9-based therapies in …
Share

17 May
Bayer and ERS Genomics Announce Licensing Agreement for Genome-Editing Patents

LEVERKUSEN, Germany & DUBLIN–(BUSINESS WIRE)–Bayer and ERS signed a patent license agreement whereby Bayer gains access to ERS’ CRISPR-Cas9 genome-editing patents for certain cross-divisional applications in Bayer’s core strategic areas. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing …
Share